• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical course and background of eight patients who discontinued secukinumab after achieving a score of 0 on the psoriasis area and severity index.

作者信息

Yasuda Masahito, Morimoto Naoko, Inoue Yuta, Ishikawa Osamu, Motegi Sei-Ichiro

机构信息

Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

出版信息

J Dermatol. 2021 Aug;48(8):e380-e381. doi: 10.1111/1346-8138.15948. Epub 2021 May 18.

DOI:10.1111/1346-8138.15948
PMID:34002889
Abstract
摘要

相似文献

1
Clinical course and background of eight patients who discontinued secukinumab after achieving a score of 0 on the psoriasis area and severity index.八名患者在银屑病面积和严重程度指数达到0分后停用司库奇尤单抗的临床病程及背景
J Dermatol. 2021 Aug;48(8):e380-e381. doi: 10.1111/1346-8138.15948. Epub 2021 May 18.
2
Unusual relapse in a psoriasis patient receiving secukinumab: Linear psoriasis.接受司库奇尤单抗治疗的银屑病患者出现罕见复发：线状银屑病。
Dermatol Ther. 2020 May;33(3):e13346. doi: 10.1111/dth.13346. Epub 2020 May 3.
3
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.司库奇尤单抗治疗指甲银屑病的临床疗效和疾病负担的影响：随机安慰剂对照 TRANSFIGURE 试验的 32 周结果。
Br J Dermatol. 2019 Nov;181(5):954-966. doi: 10.1111/bjd.17351. Epub 2019 Jan 16.
4
Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis.司库奇尤单抗诱导的一名银屑病患者手掌部水疱脓疱性皮疹
Dermatol Ther. 2020 May;33(3):e13332. doi: 10.1111/dth.13332. Epub 2020 Apr 7.
5
Successful treatment of nevoid psoriasis with Secukinumab in a pediatric patient.司库奇尤单抗成功治疗一名儿童患者的痣样银屑病。
Dermatol Ther. 2022 Jun;35(6):e15456. doi: 10.1111/dth.15456. Epub 2022 Mar 23.
6
Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study.司库奇尤单抗治疗中重度掌跖脓疱型银屑病148周的疗效和安全性：2PRECISE研究的扩展
J Am Acad Dermatol. 2021 Feb;84(2):552-554. doi: 10.1016/j.jaad.2020.06.038. Epub 2020 Jun 18.
7
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.司库奇尤单抗对银屑病患者内皮功能障碍及其他心血管疾病参数的影响：52 周研究结果
J Invest Dermatol. 2019 May;139(5):1054-1062. doi: 10.1016/j.jid.2018.10.042. Epub 2018 Nov 30.
8
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.司库奇尤单抗在清除中重度斑块状银屑病患者皮肤方面优于乌司奴单抗：CLEAR，一项随机对照试验。
J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17.
9
Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab.评估司库奇尤单抗治疗斑块型银屑病患者的血清生物标志物。
J Dermatol. 2020 May;47(5):452-457. doi: 10.1111/1346-8138.15278. Epub 2020 Mar 15.
10
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.司库奇尤单抗优化剂量治疗中重度斑块型银屑病患者：来自随机、开放标签 OPTIMISE 研究的结果。
Br J Dermatol. 2020 Feb;182(2):304-315. doi: 10.1111/bjd.18143. Epub 2019 Sep 8.